Abstract
Acute renal failure is increasingly seen as part of the multiple organ dysfunction syndrome (MODS) in critically ill patients [1, 2]. MODS is the most frequent cause of death in patients admitted to intensive care units (ICUs) [3]. Severe sepsis and septic shock are the primary causes of MODS [4, 5] and develop as a result of the host response to infection by Gram-negative and Gram-positive bacteria [6]. Sepsis encompasses a complex mosaic of interconnected events. Molecules such as bacterial lipopolysaccharides (LPS), microbial lipopeptides, microbial DNA, peptidoglycan and lipoteichoic acid interact with the Toll-like receptors (TLR) and related molecules (MD-2, MyD88), the principal sensors of the innate immune response [7–9]. Stimulus-receptor coupling activates different signal transduction pathways leading to exacerbated generation of cytokines, and phospholipase A2-dependent, arachidonic acid-derived platelet-activating factor (PAF), leukotrienes, and thromboxanes. At the plasma level, activation of the complement (C3a, C5a, and their desarginated products) and coagulation pathways interacts with the process as products generated in the fluid phase may in turn trigger and sustain cell activation. Other agents play a role in the pathophysiology of sepsis such as surface-expressed and soluble adhesion molecules, kinins, thrombin, myocardial depressant substance(s), endorphin, and heat shock proteins.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cosentino F, Chaff C, Piedmonte M (1994) Risk factors influencing survival in ICU acute renal failure. Nephrol Dial Transplant 9 (suppl 4): 179–182
Liano G, Pascual J (1996) Acute renal failure. Madrid Acute Renal Failure Study Group. Lancet 347: 479
Bellomo R, Ronco C (1998) Indications and criteria for initiating renal replacement therapy in the intensive care unit. Kidney Int Suppl 66: S106–5109
The ACCP/SCCM Consensus conference committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644–1655
Camussi G, Montrucchio G, Diminioni L, Dionigi R (1995) Septic shock: the unravelling of molecular mechanism. Nephrol Dial Transplant 10: 1808–1813
Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338: 732–736
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394–397
Shimazu R, Akashi S, Ogata H, et al (1999) MD-2 a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189: 1777–1782
Medzhitov R, Preston-Hurlburt P, Kopp E, et al (1998) My88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2: 253–258
Van Bommel EFH, Bouvy ND, So KL, et al (1995) Acute dialytic support for the critically ill: Intermittent hemodialysis versus continuous arteriovenous hemodiafiltration. Am J Nephrol 15: 192–200
Bellomo R, Mehta R (1995) Acute renal replacement in the intensive care medicine: Now and tomorrow. New Horiz 3: 760–767
Canaud B, Mion C (1995) Extracorporeal treatment of acute renal failure: methods, indications, quantified and personalized therapeutic approach. Adv Nephrol 24: 271–281
Silvester W, Bellomo R, Ronco C (1998) Continuous versus intermittent renal replacement therapy in the critically ill. In: Ronco C, Bellomo R (eds) Critical Care Nephrology. Kluwer Academic Publishers, Dordrecht, pp 1225–1238
Bellomo R, Tipping P, Boyce N (1993) Continuous veno-venous hemofiltration with dialysis cytokines from the circulation of septic patients. Crit Care Med 21: 522–526
Schetz M, Ferdinande P, Van der Berghe G, et al (1995) Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med 21: 169–176
Van Bommel EFH, Hesse CJ, Jutte NHPM, et al (1995) Cytokine kinetics during continuous hemofiltration: a laboratory and clinical study. Contrib Nephrol 116: 62–75
Bellomo R, Tipping P, Boyce N (1995) Interleukin-6 and interleukin-8 extraction during continuous venovenous-hemodiafiltration in septic acute renal failure. Renal Fail 17: 457–466
Millar AB, Armstrong L, van der Linden J, et al (1993) Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 56: 1499–1502
Journois D, Pouard P, Greely WJ, et al (1994) Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Anesthesiology 81: 1181–1189
Goldfarb S, Golper TA (1994) Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 5: 228–232
Ronco C, Tetta C, Lupi A, et al (1995) Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med 23: 99–107
Cavaillon JM, Munoz C, Fitting C, et al (1992) Circulating cytokines: The top of the iceberg? Circ Shock 38: 145–152
Reidy MA, Bowyer DE (1997) Scanning electron microscopy: morphology of aortic endothelium following injury by endotoxin and during subsequent repair. Atherosclerosis 26: 319–328
Gil LY, Rosellò AM, Torres AC, et al (2002) Modulation of soluble phases of endothelial/ leukocyte adhesion molecule 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 with interleukin lß after experimental endotoxic challenge. Crit Care Med (in press)
Dinarello CA, Cannon JC, Wolff SM, et al (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163: 1433–1440
van Deventer SJH, Bueller HR, ten Cate JW, et al (1990) Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76: 2520–2526
Rosenberg RD, Aird WC (1999) Vascular-bed specific hemostasis and hypercoagulable states. N Engl J Med 340: 1555–1564
Esmon CT (2000) The protein C pathway. Crit Care Med 28: S44 - S48
Taylor FB, Haddad PA, Hack E, et al (2001). Two-stage response to endotoxin infusion into normal human subjects:Correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med 29: 326–334
Faust SN, Levin M, Harrison OB, et al (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345: 408–416
Pinsky MR (2001) Sepsis: a pro-and anti-inflammatory disequilibrium syndrome. Contrib Nephrol 132: 354–366
Cavaillon JM, Adib-Conquy M, Cloez-Tayarani I, Fitting C (2001) Immunodepression in sepsis and SIRS assessed by ex vivo cytokine production is not a generalized phenomenon: a review. J Endotoxin Res 7: 85–93
Suffredini AF, Fromm RE, Parker MM, et al (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321: 280–287
Matrich GD, Danner RL, Ceska M, et al (1991) Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents. J Exp Med 173: 1021–1024
Michie HR, Manogue KR, Spriggs DR, et al (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318: 1481–1486
Suffredini AF, Harpel PC, Parrillo JE (1989) Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. N Engl J Med 320: 1165–1172
Kumasaka T, Quinlan W, Doyle N, et al (1996) Role of the intercellular adhesion molecule (ICAM-1) in endotoxin-induced pneumonitis using ICAM-1 anti-sense oligonucleotides, anti-ICAM-1 monoclonal antibodies and ICAM-1 mutant mice. J Clin Invest 97: 2362–2369
Volk HD, Reinke P, Krausch D, et al (1996) Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med (suppl 4 ): 5474 - S481
Cavaillon JM, Adib-Conquy M, Cloez-Tayarani I, Fitting C (2001) Immunosuppression in sepsis and SIRS assessed by ex-vivo cytokine production is not a generalized phenomenon: a review. J Endotoxin Res 7: 85–93
Munoz C, Carlet J, Fitting C, et al (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88: 1747–1754
Randow F, Syrbe V, Meisel C, et al (1995) Mechanism of endotoxin desensitization: involvement of interleukin-10 and transforming growth factor. J Exp Med 181: 1887–1892
Brandtzaeg P, Osnes L, Ostebo R, et al (1996) Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med 184: 51–60
Marie C, Muret J, Fitting C, et al (2000) Interleukin-1 receptor antagonist production during infectious and noninfectious systemic inflammatory response syndrome. Crit Care Med 28: 2277–2282
Granowitz EV, Porat R, Mier JW, et al (1993) Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells in healthy humans. J Immunol 151: 1637–1645
Knudsen PJ, Dinarello CA, Strom TB (1986) Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 137: 3189–3194
Bone RC, Grodzin CJ, Balk RA (1997) Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 112: 235–243
Adib-Conquy M, Adrie C, Moine P, et al (2000) NF-kappaB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med 162: 1877–1883
Gogos CA, Drosou E, Bassaris HP, Skoutelis A (2000) Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181: 176–180
Parrillo JE, Burch C, Stelhamer JH, et al (1985) A circulating myocardial depressant substance in humans with septic shock: septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 76: 1539–1553
Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25: 1095–1100
Abraham E, Glauser MP, Butler T, et al (1997) p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45–2081 study group. JAMA 277: 1531–1538
Fisher CJ, Agosti JM, Opal SM (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334: 1697–1702
Echtenacher B, Falk W, Mannel D, Krammer PH (1990) Requirement of endogenous tumour necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145: 3762–3766
van der Meer JWM (1988) The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy 1: 19–25
Ronco C, Ricci Z, Bellomo R (2001) Importance of increased ultrafiltration volume and impact on mortality: sepsis and cytokine story and the role of continuous veno-venous hemofiltration. Curr Opin Nephrol Hypertens 10: 755–761
Silvester W (1997) Mediator removal with CRRT: complement and cytokines. Am J Kidney Dis 30 (suppl 4): 538 - S43
Hoffmann JN, Hartl WH, Deppisch R, et al (1995) Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 48: 1563–1570
Gasche Y, Pascual M, Suter PM, et al (1996) Complement depletion during haemofiltration with polyacilonitrile membranes. Nephrol Dial Transplant 11: 117–119
Goldfarb S, Golper TA (1994) Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 5: 228–232
Kellum JA, Johnson JP, Kramer D, et al (1998) Diffusive vs. convective therapy: effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome. Crit Care Med 26: 1995–2000
Braun N, Giolai M, Rosenfeld S, et al (1993) Clearance of interleukin-6 during continuous veno-venous hemofiltration in patients with septic shock. A prospective, controlled clinical study. J Am Soc Nephrol 4: 336 (abst)
Mariano F, Tetta C, Guida GE, Triolo G, Camussi G (2001) Hemofiltration reduces the priming activity on neutrophil chemiluminescence in septic patients. Kidney Int 60: 1598–1605
Mariano F, Guida G, Donati D, et al (1999) Production of platelet-activating factor in patients with sepsis-associated acute renal failure. Nephrol Dial Transplant 14: 1150–1157
Sander A, Armbruster W, Sander B, et al (1997) Haemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 23: 878–884
De Vriese AS, Colardyn FA, Philippe JJ, et al (1999) Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 10: 846–853
Cole L, Bellomo R, Journois D, et al (2002) A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 30: 100–106
Heering P, Morgera S, Schmitz FJ, et al (1997) Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 23: 288–296
Ronco C, Brendolan A, Lonnemann G, et al (2002) A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 30: 1250–1255
De Vriese AS, Vanholder RC, Pascual M, et al (1999) Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med 25: 903–910
Grootendorst AF, van Bommel EFH, van der Hoven B, et al (1992) High volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. J Crit Care 7: 67–75
Grootendorst AF, van Bommel EFH, van Leengoed LA, et al (1993) Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care 8: 161–169
Grootendorst AF, van Bommel EFH, van Leengoed LA, et al (1994) High volume hemofiltration improves hemodynamics and survival of pigs exposed to gut ischemia and reperfusion. Shock 2: 72–78
Lee PA, Matson JR, Pryor RW, Hinshaw LB (1993) Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 21: 914–924
Rogiers P, Zhang H, Smail N, et al (1999) Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med 27: 1848–1855
Yekebas EF, Eisenberger CF, Ohnesorge H, et al (2001) Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Grit Care Med 29: 1423–1430
Nagashima M, Shin’oka T, Nollert G, et al (1998) High-volume continuous hemofiltration during cardiopulmonary bypass attenuates pulmonary dysfunction in neonatal lambs after deep hypothermic circulatory arrest. Circulation 98 (suppl 19):II378–384
Bellomo R, Kellum JA, Gandhi CR, Pinsky MR (2000) The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 161: 1429–1436
Ronco C, Bellomo R, Homel P, et al (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356: 26–30
Journois D, Israel Biet D, Pouard P, et al (1996) High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 85: 965–976
Oudemans-van Straaten HM, Bosman RJ, et al (1999) Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis. Intensive Care Med 25: 814–821
Cole L, Bellomo R, Journois D, et al (2001) High-volume hemofiltration in human septic shock. Intensive Care Med 27: 978–986
Honore PM, Jamez J, Wauthier M, et al (2000) Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 28: 3581–3587
Lee PA, Weger G, Pryor RW, Matson JR (1998) Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy for staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 26: 730–737
Kline JA, Gordon BE, Williams C, et al (1999) Large-pore hemodialysis in acute endotoxin shock. Crit Care Med 27: 588–596
Morgera S, Buder W, Lehmann C, et al (2000) High cut off membrane haemofiltration in septic patients with multiorgan failure. A preliminary report. Blood Purif 18: 61 (abst)
Reeves JH, Butt WW, Shann F, et al and the Plasmafiltration in Sepsis Study Group (1999). Continuous plasmafiltration in sepsis syndrome. Crit Care Med 27: 2096–2104
Tetta C, Cavaillon JM, Schulze M, et al (1998) Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption. Nephrol Dial Transplant 13: 1458–1464
Tetta C, Gianotti L, Cavaillon JM, et al (2000) Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 28: 1526–1533
Lonnemann G, Bechstein M, Linnenweber S, et al (1999) Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int Suppl 72: S84 - S87
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Tetta, C., Bellomo, R., Ronco, C. (2003). Interpreting the Mechanisms of CRRT in Sepsis: The Peak Concentration Hypothesis. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-5548-0_62
Download citation
DOI: https://doi.org/10.1007/978-1-4757-5548-0_62
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4757-5550-3
Online ISBN: 978-1-4757-5548-0
eBook Packages: Springer Book Archive